Efruxifermin for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Jul 2024: Trial registered, NCT06528314
  2. 4 Oct 2024: Trial started, NCT06528314

The trials

NCT06528314: A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

State
Under way
Phase
Phase 3
People
2,150 planned
Started
4 Oct 2024
Primary completion
Feb 2030
Arms
EFX 50 mg
Results
None posted
  1. 30 Jul 2024: Trial registered
  2. 4 Oct 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.